India, June 15 -- India's aesthetics market has expanded in a regulatory grey zone for years. Injectable products that altered physiological functions often occupied an uncertain position between cosmetics and drugs. This allowed businesses to leverage differing regulatory pathways depending on how products were positioned in the market. The ambiguity is beginning to disappear with the Central Drugs Standard Control Organisation (CDSCO) clarifying that injectable cosmetic products fall within the drug regulatory framework.

While much of the discussion has focused on consumer safety, the development carries broader implications for India's MedTech and healthcare innovation ecosystem. The clarification is less about restricting market grow...